Company news
Telix Pharmaceuticals Limited (ASX:TLX) news
Telix Pharmaceuticals Limited news releases on 6ix. Latest, Apr 22, 2025: Telix Reports US$186M Q1 Revenue, Up 62% YOY
Press releases — page 3
Telix Reports US$186M Q1 Revenue, Up 62% YOY
April 22, 2025
FDA Approves New Prostate Cancer Imaging Agent Gozellix
March 20, 2025
Telix Completes FAP-Targeting Theranostic Acquisition
March 11, 2025
FDA accepts BLA and grants priority review for Zircaix
February 25, 2025
Telix Announces Change in Reporting Currency to USD
February 24, 2025
2024 Full Year Results Presentation
February 20, 2025
2024 Full Year Results Announcement
February 20, 2025
Appendix 4E and 2024 Annual Report
February 20, 2025
Illuccix Approved in the United Kingdom
February 12, 2025
Telix Completes Acquisition of Tx Assets, Biologics Platform
January 30, 2025
Telix Completes Acquisition of RLS (USA) Inc
January 27, 2025
Illuccix Receives European Approval
January 16, 2025
Telix JP Morgan Healthcare Conference 2025 Presentation
January 13, 2025
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
January 13, 2025
Presentation to Accompany Biologics Platform Acquisition
January 12, 2025
TLX to Acquire Next-Gen Therapeutics and Biologics Platform
January 12, 2025
Presentation to Accompany FAP-Targeting Acquisition
November 18, 2024
Telix Adds FAP-Targeting Theranostic Candidates to Pipeline
November 18, 2024
CMS payment improvement decision for radiopharma diagnostics
November 3, 2024
FDA accepts NDA and grants priority review for Pixclara
October 23, 2024
Telix Files Form 20-F Registration Statement for Nasdaq ADS
October 17, 2024
Telix Q3 2024 Revenue and Business Update
October 17, 2024
Telix to Acquire RLS for US Manufacturing and Distribution
September 22, 2024
Telix Submits NDA for TLX101-CDx Brain Cancer Imaging Agent
August 27, 2024
Telix 1H 2024 Results Release
August 22, 2024
Telix 1H 2024 Results Presentation
August 22, 2024
Telix 1H 2024 Appendix 4D and Interim Report
August 22, 2024
Telix Completes A$650 Million of Convertible Bonds
July 30, 2024
Convertible Bond Cleansing Notice
July 29, 2024
Telix Successfully Prices A$650M Convertible Bonds
July 23, 2024
Telix Announces A$600 Million Convertible Bonds Offering
July 23, 2024
Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade
July 17, 2024
CMS proposes payment improvement for radiopharma diagnostics
July 11, 2024
Telix Elects to Withdraw from Proposed U.S. Listing
June 13, 2024
Trading Halt
June 12, 2024
Telix Launches Proposed US IPO
June 5, 2024
Telix Completes TLX250-CDx (Zircaix) BLA Submission
June 2, 2024
ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
May 30, 2024
Response to ASX Query
May 28, 2024
Telix Submits NDA for New Prostate Cancer Imaging Agent
May 26, 2024
Telix Annual General Meeting - Presentation
May 22, 2024
Telix Annual General Meeting - Chairman and CEO Addresses
May 22, 2024
Telix Completes Proof-of-Concept Study for Alpha Therapy
May 20, 2024
Telix has Filed Registration Statement for Proposed US IPO
May 19, 2024
Telix Reports Q1 2024 Financial Performance
May 17, 2024
Telix Completes Acquisition of QSAM
May 2, 2024
Telix Q1 2024 Revenue and Business Update
April 17, 2024
TLX101-CDx (Pixclara) Granted FDA Fast Track Designation
April 15, 2024
Telix Completes Acquisition of ARTMS
April 11, 2024
Telix Completes Acquisition of IsoTherapeutics
April 8, 2024